<DOC>
	<DOCNO>NCT00868972</DOCNO>
	<brief_summary>Atherosclerotic renal artery stenosis ( ARAS ) associate progressive loss renal function , refractory hypertension flush edema , responsible mortality morbidity , especially elderly . Current treatment include restoration renal arterial lumen endovascular stent placement and/or intensive medical therapy . There unanimous consent patient could benefice endovascular procedure due high rate renal adverse event especially link atheroembolic disease . Recently , renal revascularization use device consent distal embolic protection kidney demonstrate `` safe '' auxiliary procedure non randomize study . Interestingly atheromatous debris detect 60 80 % device analyzed procedure suggest device could prevent atheroembolism substantial proportion patient . On hand , randomize control study prove renal stent distal embolic protection superior renal stent alone preserve kidney function . Therefore , present study aim compare effect renal artery stent placement without distal embolic protection renal function ARAS patient . Method : Patients ARAS ≥70 % hypertension responsive least 2 antihypertensive medication and/or renal failure ( estimate GFR &lt; 60 mL/min/1.73 m2 randomly assign stent placement alone stent placement distal embolic protection ( FILTER WIRE EX ; Cordis Endovascular , USA ) . Other medication consist statin , anti-hypertensive drug antiplatelet therapy . Patients follow 3 month . The primary outcome study statistical significant difference kidney function measure Cr clearance cystatin C level 2 group three month . The trial include 150 patient .</brief_summary>
	<brief_title>Renal Stenting With Distal Atheroembolic Protection</brief_title>
	<detailed_description>This randomized trial patient ostial ARAS refractory hypertension renal failure . Patients randomize : ( ) renal artery stent placement distal embolic protection ( ii ) renal artery stent placement without distal embolic protection To group optimal medical treatment consist antihypertensive , lipid-lowering antiplatelet therapy add . Patients ostial ARAS associate estimate GFR &lt; 60 mL/min/1.73m2 accord MDRD formula and/or refractory hypertension enrol trial . Ostial ARAS define luminal reduction ≥70 % renal artery within 1 cm aortic wall , presence atherosclerotic change aorta . Stenosis evaluation perform intra-arterial angiography . Medical therapy : Irrespective baseline serum cholesterol value , patient treat lipid-lowering therapy : 10 mg rosuvastatin . Any lipid-lowering medication currently use discontinue replaced rosuvastatin . Hypertension treat follow drug : ACE-inhibitors together , loop diuretic , dihydropyridine calcium antagonist . The target BP &lt; 140/90 mmHg . Patients receive anti-platelet therapy , aspirin 75-100 mg/od plus ticlopidine 250 mg bid one month . Considering smoke major renal risk factor , smoker advise stop . Medical therapy identical two treatment arm . In group patient start aspirin 100 mg/od ticlopidine 250 mg bid least five day admission . The stent ( Palmaz-Corinthian IQ/Palmaz Genesis , Johnson &amp; Johnson Medical , NV/SA ) place in-patient admission accord standardize protocol . To Patients randomize embolic protection device ( FILTER WIRE EX ; Cordis Endovascular , USA ) place distal arterial stenosis stent placement . Randomization do use random number table The people aware assigned procedure radiologist ' team . Researchers technician follow patient analyze plasma urinary sample blind assigned treatment . Clinical follow-up schedule 1 3 month . Analysis result : The difference mean change cystatin C respect baseline treatment arm assess include 95 % confidence interval ( 95 % CI ) . The effect renal function two treatment strategy evaluate multivariate linear regression analysis , consider also eventual role age , smoking , diabetes , lipid level , proteinuria , bilateral unilateral renal artery stenosis , BP renal function baseline</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Renal Artery Obstruction</mesh_term>
	<mesh_term>Hypertension , Renovascular</mesh_term>
	<criteria>Age &gt; 18 year Ostial atherosclerotic renal artery stenosis ≥70 % intraarterial angiography Well document history hypertension ( &gt; 140/90 mmHg ) non responsive use 2 antihypertensive medication and/or Estimated glomerular filtration rate &lt; 60 ml/min/1.73m2 accord MDRD formula , two occasion within one month Declined informed consent Renal longitudinal diameter &lt; 8 cm Any anatomical reason make impossible PTRA position distal embolic protection device Estimated glomerular filtration rate &lt; 30 ml/min/1.73m2 accord MDRD formula dialysis Allergy contrast medium use angiography Other condition associate ( within 6 month ) poor prognosis Myocardial infarction , unstable angina stroke &lt; 1 month plan date inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Renal Artery Obstruction</keyword>
	<keyword>renovascular hypertension</keyword>
	<keyword>stent</keyword>
	<keyword>Kidney Failure</keyword>
	<keyword>embolic protection</keyword>
</DOC>